Related Experiment Videos

Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis

T W Kensler1, P M Dolan, S J Gange

  • 1Department of Environmental Health Sciences and Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA. tkensler@jhsph.edu

Carcinogenesis
|June 30, 2000
PubMed

Insights

New vitamin D analogs (deltanoids) show promise for cancer prevention. A novel hybrid deltanoid effectively inhibited tumor formation in mice without causing harmful calcemic activity, offering a safer alternative to calcitriol.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Endocrinology

Background:

  • Development of vitamin D analogs (deltanoids) aims to separate therapeutic effects from adverse calcemic activity.
  • Calcitriol (1 alpha, 25-dihydroxyvitamin D(3)) possesses both beneficial and detrimental properties.

Purpose of the Study:

  • To synthesize and evaluate novel deltanoids with modified structures for enhanced chemopreventive efficacy and reduced calcemic effects.
  • To assess the in vitro and in vivo activity of these analogs against cancer development.

Main Methods:

  • Synthesis of deltanoids with modifications at the 1alpha- and/or 25-hydroxyl groups, including 1 beta-hydroxymethyl and side chain alterations.
  • In vitro assessment of antiproliferative activity and inhibition of ornithine decarboxylase induction.
  • In vivo evaluation in a mouse skin carcinogenesis model using 7,12-dimethylbenz[a]anthracene initiation and 12-O-tetradecanoylphorbol-13-acetate promotion.

Main Results:

  • A hybrid deltanoid with 1 beta-hydroxymethyl alteration, C,D ring unsaturation, and side chain modifications demonstrated potent antiproliferative activity comparable to calcitriol.
  • Several non-calcemic sulfone analogs also showed activity in assays.
  • In vivo, all tested deltanoids inhibited papilloma formation without affecting body weight or causing significant hypercalcemia. The hybrid analog significantly reduced tumor incidence (28%) and multiplicity (63%).

Conclusions:

  • Novel deltanoids, particularly the hybrid analog, offer a promising strategy for cancer chemoprevention with an improved safety profile.
  • Structural modifications, including A ring and side chain alterations, are crucial for developing potent and safe vitamin D analogs.
  • These findings advance the understanding of structure-activity relationships for vitamin D analogs with potential medicinal applications.

Related Concept Videos